A recent review by UK and Canadian scientists has examined the effects glucagon-like peptide-1 receptor agonists (GLP-1) drugs may have on cognitive functioning and mental health issues has found mixed results.
While some studies showed the drugs offer neuro-protective benefits, other studies cautioned that some medications may increase depression and suicidal ideality.
The review, published in Nature Mental Health, utilised data from hundreds of clinical studies, preclinical studies, controlled trials and meta- analyses to learn more about how GLP- 1 medications impact the brain.
More than 100 preclinical research studies suggested GLP-1 drugs could protect against cognitive decline; the study found ‘these findings are significant to people with Alzheimer’s and Parkinson’s’ and the researchers also noted ‘GLP-1 drugs offer protection by reducing harmful brain proteins, inflammation and insulin resistance’.
However, the researchers also found people with anxiety and depression sometimes experience worsened symptoms; some case reports noted concerns over exenatide and semaglutide worsening depressive symptoms, and a larger study suggested a slightly increased risk of suicidal behaviour with liraglutide.
The authors noted: ‘Overall, as GLP-1RAs become increasingly prescribed, further pharmaco-vigilance studies are warranted.’
